Another Polish study from 2021, which included 313 AIH patients, could not confirm the effect of the PNPLA3 polymorphism on the clinical endpoints in AIH, but demonstrated a link of the PNPLA3 risk allele to higher MELD scores. The gene discussed is PNPLA3; the disease is autoimmune hepatitis.